Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04446117 · ClinicalTrials.gov registry record · Phase 3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
A Phase 3 study of Prostate Adenocarcinoma and Metastatic Prostate Cancer, sponsored by Exelixis.
- Active
- Registry status
- Phase 3
- Development phase
- 575
- Enrollment target
- 20
- Study locations
NCT04446117 is a Phase 3 study of Prostate Adenocarcinoma and Metastatic Prostate Cancer that is active but no longer recruiting, run by Exelixis. The registered enrollment target is 575 participants, above the 213-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (170% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT04446117, a Phase 3 study of Prostate Adenocarcinoma and Metastatic Prostate Cancer, is active but no longer recruiting, sponsored by Exelixis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 575 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Prednisone
- DRUG Cabozantinib
- DRUG Enzalutamide
- DRUG Abiraterone Acetate
Study Locations (20)
California
- Exelixis Clinical Site #42 - Duarte
- Exelixis Clinical Site #2 - Fullerton
- Exelixis Clinical Site #224 - La Jolla
- Exelixis Clinical Site #3 - Marina del Rey
- Exelixis Clinical Site #114 - San Diego
- Exelixis Clinical Site #125 - Santa Monica
- Exelixis Clinical Site #245 - Stanford
Colorado
- Exelixis Clinical Site #91 - Aurora
- Exelixis Clinical Site #14 - Denver
Connecticut
- Yale University School of Medicine - New Haven
- Yale University, School of Medicine - New Haven
Arizona
- Exelixis Clinical Site #4 - Tucson
Florida
- Exelixis Clinical Site #108 - Miami
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Kansas
- Exelixis Clinical Site #215 - Westwood
Kentucky
- Exelixis Clinical Site #242 - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 575 participants |
| Start Date | 2020-10-19 |
| Est. Completion | 2026-10-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04446117
The ClinicalTrials.gov registry entry for NCT04446117 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 575 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 213-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (170% higher). The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Atezolizumab is the first listed.
NCT04446117 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04446117 about?
NCT04446117 is a clinical study titled "Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC". This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have prev...
What is the current status of trial NCT04446117?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 575 participants. The study started on 2020-10-19. Estimated completion is 2026-10-16.
What conditions does trial NCT04446117 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Metastatic Prostate Cancer.
What interventions are being tested in trial NCT04446117?
The interventions under investigation include: Atezolizumab (DRUG), Prednisone (DRUG), Cabozantinib (DRUG), Enzalutamide (DRUG), Abiraterone Acetate (DRUG).
Who is sponsoring clinical trial NCT04446117?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04446117 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
RECRUITING · Phase 3
-
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
RECRUITING · Phase 3
-
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RECRUITING · Phase 3
-
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
RECRUITING · Phase 3
-
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.